Compare Procaps Group SA with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 253 Million (Micro Cap)
6.00
NA
0.00%
252.18
-81.22%
-4.96
Revenue and Profits:
Net Sales:
111 Million
(Quarterly Results - Dec 2023)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-64.14%
0%
-64.14%
6 Months
-98.21%
0%
-98.21%
1 Year
-95.26%
0%
-95.26%
2 Years
-99.07%
0%
-99.07%
3 Years
-99.41%
0%
-99.41%
4 Years
-99.69%
0%
-99.69%
5 Years
-99.75%
0%
-99.75%
Procaps Group SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
651.70%
EBIT Growth (5y)
258.38%
EBIT to Interest (avg)
2.09
Debt to EBITDA (avg)
3.52
Net Debt to Equity (avg)
6.92
Sales to Capital Employed (avg)
43.16
Tax Ratio
22.94%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.40%
ROCE (avg)
22.00%
ROE (avg)
3.61%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
-4.96
EV to EBIT
10.47
EV to EBITDA
7.44
EV to Capital Employed
2.87
EV to Sales
1.10
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
27.43%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 1 Schemes (0.03%)
Foreign Institutions
Held by 3 Foreign Institutions (0.16%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ
Dec'23
Sep'23
Change(%)
Net Sales
111.10
118.40
-6.17%
Operating Profit (PBDIT) excl Other Income
18.30
18.20
0.55%
Interest
12.90
11.70
10.26%
Exceptional Items
-19.30
8.70
-321.84%
Consolidate Net Profit
-1.40
8.20
-117.07%
Operating Profit Margin (Excl OI)
117.70%
111.30%
0.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2023 is -6.17% vs 7.54% in Sep 2023
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2023 is -117.07% vs -69.63% in Sep 2023
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
373.80
423.70
-11.78%
Operating Profit (PBDIT) excl Other Income
-11.50
62.80
-118.31%
Interest
45.50
45.80
-0.66%
Exceptional Items
7.00
5.50
27.27%
Consolidate Net Profit
-68.30
40.30
-269.48%
Operating Profit Margin (Excl OI)
-84.50%
105.30%
-18.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -11.78% vs 3.37% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -269.48% vs -5.18% in Dec 2023
About Procaps Group SA 
Procaps Group SA
Pharmaceuticals & Biotechnology
Union Acquisition Corp. II is a blank check company. The Company is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. It intends to focus on business located in Latin America. It is focused on businesses in sectors, such as natural resources, industrial operations and financial services and technology sectors. It is not engaged in any operations nor generated any revenues.






